Interleukin-1 in tumor progression, therapy, and prevention
Interleukin-1 (IL-1) is a key orchestrator of inflammation and plays an important role in tumor progression. Based on preclinical models and human genetic associations, we surmise that targeting IL-1 should be considered in treating selected human tumors as well as in a prevention and/or interceptio...
Saved in:
| Published in | Cancer cell Vol. 39; no. 8; pp. 1023 - 1027 |
|---|---|
| Main Authors | , |
| Format | Journal Article |
| Language | English |
| Published |
United States
Elsevier Inc
09.08.2021
|
| Subjects | |
| Online Access | Get full text |
| ISSN | 1535-6108 1878-3686 1878-3686 |
| DOI | 10.1016/j.ccell.2021.04.011 |
Cover
| Abstract | Interleukin-1 (IL-1) is a key orchestrator of inflammation and plays an important role in tumor progression. Based on preclinical models and human genetic associations, we surmise that targeting IL-1 should be considered in treating selected human tumors as well as in a prevention and/or interception setting.
Interleukin-1 (IL-1) is a key orchestrator of inflammation and plays an important role in tumor progression. Based on preclinical models and human genetic associations, we surmise that targeting IL-1 should be considered in treating selected human tumors as well as in a prevention and/or interception setting. |
|---|---|
| AbstractList | Interleukin-1 (IL-1) is a key orchestrator of inflammation and plays an important role in tumor progression. Based on preclinical models and human genetic associations, we surmise that targeting IL-1 should be considered in treating selected human tumors as well as in a prevention and/or interception setting.Interleukin-1 (IL-1) is a key orchestrator of inflammation and plays an important role in tumor progression. Based on preclinical models and human genetic associations, we surmise that targeting IL-1 should be considered in treating selected human tumors as well as in a prevention and/or interception setting. Interleukin-1 (IL-1) is a key orchestrator of inflammation and plays an important role in tumor progression. Based on preclinical models and human genetic associations, we surmise that targeting IL-1 should be considered in treating selected human tumors as well as in a prevention and/or interception setting. Interleukin-1 (IL-1) is a key orchestrator of inflammation and plays an important role in tumor progression. Based on preclinical models and human genetic associations, we surmise that targeting IL-1 should be considered in treating selected human tumors as well as in a prevention and/or interception setting. Interleukin-1 (IL-1) is a key orchestrator of inflammation and plays an important role in tumor progression. Based on preclinical models and human genetic associations, we surmise that targeting IL-1 should be considered in treating selected human tumors as well as in a prevention and/or interception setting. |
| Author | Mantovani, Alberto Garlanda, Cecilia |
| Author_xml | – sequence: 1 givenname: Cecilia surname: Garlanda fullname: Garlanda, Cecilia email: cecilia.garlanda@humanitasresearch.it organization: Humanitas Research Hospital—IRCCS, Via Manzoni 56, 20089 Rozzano, Milan, Italy – sequence: 2 givenname: Alberto surname: Mantovani fullname: Mantovani, Alberto email: alberto.mantovani@humanitasresearch.it organization: Humanitas Research Hospital—IRCCS, Via Manzoni 56, 20089 Rozzano, Milan, Italy |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/33989512$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kMtKLDEURYMovr_gwqWGDqwyqbwRByK-QHCi45BOTnvTtzrVJinBvzdt68SBoxw4ex2y1wHajmMEhP4Q3BFMxNmicw6GoetxTzrMOkzIFtonSqqWCiW268wpbwXBag8d5LzAlSJS76I9SrXSnPT76Pw-FkgDTP9DbEkTYlOm5ZiaVRpfEuQcxnjalH-Q7Or9tLHR1w28QSx1cYR25nbIcPz1HqLnm-unq7v24fH2_uryoXUMs9JSTiXnTmqvGbZSeI4ZSK2lkFQ6P5MeOJuRmZLOKeq9Uwys0IKzuZ1TT-ghOtncrZ96nSAXswx5Xd1GGKdset4rogiTokb_fkWn2RK8WaWwtOndfBeuAb0JuDTmnGBuXCh23aYkGwZDsFnLNQvzKdes5RrMTJVbWfqD_T7_O3WxoaAqeguQTHYBogMfErhi_Bh-5T8A-S2S3g |
| CitedBy_id | crossref_primary_10_1016_j_intimp_2022_109430 crossref_primary_10_1016_j_jddst_2024_106376 crossref_primary_10_1172_jci_insight_157788 crossref_primary_10_1136_jitc_2021_004047 crossref_primary_10_1016_j_prp_2022_154069 crossref_primary_10_1002_mco2_181 crossref_primary_10_3390_nu16142372 crossref_primary_10_1038_s41573_022_00520_5 crossref_primary_10_2139_ssrn_4194555 crossref_primary_10_1016_j_cmet_2022_11_001 crossref_primary_10_1007_s10522_024_10152_4 crossref_primary_10_1038_s41467_023_40314_w crossref_primary_10_3390_ijms25158085 crossref_primary_10_1186_s13045_024_01578_x crossref_primary_10_1016_j_ccell_2024_04_002 crossref_primary_10_1161_ATVBAHA_124_319863 crossref_primary_10_1172_JCI175127 crossref_primary_10_3389_fimmu_2022_804641 crossref_primary_10_1093_jmcb_mjad053 crossref_primary_10_1021_acs_bioconjchem_2c00548 crossref_primary_10_7554_eLife_79895 crossref_primary_10_1016_j_molcel_2023_05_011 crossref_primary_10_1016_j_biopha_2024_117229 crossref_primary_10_1002_ddr_22246 crossref_primary_10_1016_j_canlet_2024_216833 crossref_primary_10_2147_JIR_S390915 crossref_primary_10_3892_etm_2024_12775 crossref_primary_10_1038_s41577_024_01103_8 crossref_primary_10_1016_j_critrevonc_2024_104362 crossref_primary_10_1016_j_smim_2022_101642 crossref_primary_10_3389_fimmu_2024_1395165 crossref_primary_10_1080_14728222_2025_2472042 crossref_primary_10_3390_cells13030233 crossref_primary_10_1038_s41467_024_50880_2 crossref_primary_10_1016_j_jatmed_2024_09_001 crossref_primary_10_3390_cells12010138 crossref_primary_10_3390_life13122261 crossref_primary_10_1111_jgh_16674 crossref_primary_10_3892_mmr_2024_13283 crossref_primary_10_1038_s41423_024_01216_z crossref_primary_10_1016_j_biopha_2023_114560 crossref_primary_10_1016_j_fct_2024_114451 crossref_primary_10_1158_2159_8290_CD_22_1013 crossref_primary_10_3390_antib11030046 crossref_primary_10_1158_1078_0432_CCR_24_1690 crossref_primary_10_1186_s12943_025_02227_8 crossref_primary_10_1038_s41568_022_00462_5 crossref_primary_10_1126_science_adn0327 crossref_primary_10_1016_j_ccell_2024_09_015 crossref_primary_10_1681_ASN_0000000000000191 crossref_primary_10_1038_s41467_024_55083_3 crossref_primary_10_1158_0008_5472_CAN_21_0501 crossref_primary_10_1186_s13046_023_02748_4 crossref_primary_10_1002_ejhf_3636 crossref_primary_10_1038_s41586_023_06685_2 crossref_primary_10_3389_fonc_2023_1202093 crossref_primary_10_1016_j_semarthrit_2023_152284 crossref_primary_10_4251_wjgo_v16_i3_945 crossref_primary_10_1186_s12964_024_01771_y crossref_primary_10_1038_s41416_022_01893_5 crossref_primary_10_4110_in_2024_24_e38 crossref_primary_10_1016_j_lfs_2023_122276 crossref_primary_10_1016_j_bbcan_2022_188758 crossref_primary_10_1515_fzm_2024_0012 crossref_primary_10_1002_advs_202105240 crossref_primary_10_1016_j_critrevonc_2023_104200 crossref_primary_10_1002_hsr2_1522 crossref_primary_10_1016_j_lfs_2024_122539 crossref_primary_10_1016_j_annonc_2022_09_156 crossref_primary_10_1016_j_oraloncology_2024_107078 crossref_primary_10_1186_s40168_024_01907_9 crossref_primary_10_1016_j_xfss_2022_09_004 crossref_primary_10_1126_sciadv_adi1827 crossref_primary_10_1073_pnas_2405644121 crossref_primary_10_1186_s13045_024_01621_x crossref_primary_10_1016_j_onano_2023_100134 crossref_primary_10_1111_febs_17312 |
| Cites_doi | 10.1038/s41591-018-0036-4 10.1111/imr.12620 10.1016/S0140-6736(17)32247-X 10.1158/0008-5472.CAN-18-0413 10.1016/S1470-2045(17)30006-2 10.1016/j.ccell.2019.04.003 10.1073/pnas.1812266115 10.1158/0008-5472.CAN-19-3176 10.1016/j.immuni.2019.03.012 10.1126/science.1232227 10.1038/nrclinonc.2017.101 10.1016/S0140-6736(00)04046-0 10.1007/s10555-006-9004-4 10.1158/0008-5472.CAN-19-2080 |
| ContentType | Journal Article |
| Copyright | 2021 Elsevier Inc. Copyright © 2021 Elsevier Inc. All rights reserved. |
| Copyright_xml | – notice: 2021 Elsevier Inc. – notice: Copyright © 2021 Elsevier Inc. All rights reserved. |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1016/j.ccell.2021.04.011 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1878-3686 |
| EndPage | 1027 |
| ExternalDocumentID | 33989512 10_1016_j_ccell_2021_04_011 S1535610821002191 |
| Genre | Research Support, Non-U.S. Gov't Journal Article Review |
| GroupedDBID | --- --K 0R~ 1~5 29B 2WC 4.4 457 4G. 53G 5GY 62- 6J9 7-5 AACTN AAEDT AAEDW AAFTH AAIAV AAKRW AAKUH AALRI AAUCE AAVLU AAXUO ABJNI ABMAC ABMWF ABVKL ACGFO ACGFS ADBBV ADEZE ADJPV AEFWE AENEX AEXQZ AFTJW AGKMS AITUG ALKID ALMA_UNASSIGNED_HOLDINGS AMRAJ ASPBG AVWKF AZFZN BAWUL CS3 DIK DU5 E3Z EBS F5P FCP FDB FEDTE FIRID HVGLF IH2 IHE IXB J1W JIG M3Z M41 O-L O9- OK1 P2P RCE ROL RPZ SES SSZ TR2 UDS WQ6 ZA5 5VS AAFWJ AAIKJ AAMRU AAQFI AAYWO AAYXX ABDGV ACVFH ADCNI ADVLN AEUPX AFPUW AGCQF AGHFR AIGII AKAPO AKBMS AKRWK AKYEP APXCP CITATION EJD HZ~ OZT RIG UHS 0SF CGR CUY CVF ECM EIF NPM 7X8 EFKBS |
| ID | FETCH-LOGICAL-c404t-353755c79d940a76d504e79976737cdb7de54b1b87cc83ddc84ea69654faf3d13 |
| IEDL.DBID | IXB |
| ISSN | 1535-6108 1878-3686 |
| IngestDate | Fri Sep 05 08:40:14 EDT 2025 Wed Feb 19 02:27:13 EST 2025 Thu Apr 24 23:03:28 EDT 2025 Tue Jul 01 01:26:25 EDT 2025 Fri Feb 23 02:44:10 EST 2024 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 8 |
| Language | English |
| License | Copyright © 2021 Elsevier Inc. All rights reserved. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c404t-353755c79d940a76d504e79976737cdb7de54b1b87cc83ddc84ea69654faf3d13 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23 |
| OpenAccessLink | http://www.cell.com/article/S1535610821002191/pdf |
| PMID | 33989512 |
| PQID | 2528181476 |
| PQPubID | 23479 |
| PageCount | 5 |
| ParticipantIDs | proquest_miscellaneous_2528181476 pubmed_primary_33989512 crossref_citationtrail_10_1016_j_ccell_2021_04_011 crossref_primary_10_1016_j_ccell_2021_04_011 elsevier_sciencedirect_doi_10_1016_j_ccell_2021_04_011 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2021-08-09 |
| PublicationDateYYYYMMDD | 2021-08-09 |
| PublicationDate_xml | – month: 08 year: 2021 text: 2021-08-09 day: 09 |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Cancer cell |
| PublicationTitleAlternate | Cancer Cell |
| PublicationYear | 2021 |
| Publisher | Elsevier Inc |
| Publisher_xml | – name: Elsevier Inc |
| References | Das, Shapiro, Vucic, Vogt, Bar-Sagi (bib4) 2020; 80 Apte, Dotan, Elkabets, White, Reich, Carmi, Song, Dvozkin, Krelin, Voronov (bib1) 2006; 25 Kaplanov, Carmi, Kornetsky, Shemesh, Shurin, Shurin, Dinarello, Voronov, Apte (bib7) 2019; 116 Khazim, Azulay, Kristal, Cohen (bib8) 2018; 281 Wong, Baum, Silvestro, Beste, Bharani-Dharan, Xu, Wang, Wang, Prescott, Krajkovich (bib13) 2020; 80 Balkwill, Mantovani (bib2) 2001; 357 Norelli, Camisa, Barbiera, Falcone, Purevdorj, Genua, Sanvito, Ponzoni, Doglioni, Cristofori (bib10) 2018; 24 Segovia, Russo, Jeldres, Mahmoud, Perez, Duhalde, Charnet, Rousset, Victoria, Veigas (bib12) 2019; 35 Hickish, Andre, Wyrwicz, Saunders, Sarosiek, Kocsis, Nemecek, Rogowski, Lesniewski-Kmak, Petruzelka (bib6) 2017; 18 Coussens, Zitvogel, Palucka (bib3) 2013; 339 Mantovani, Dinarello, Molgora, Garlanda (bib9) 2019; 50 Fridman, Zitvogel, Sautès-Fridman, Kroemer (bib5) 2017; 14 Wu, Xu, Martinek, Young, Banchereau, George, Turner, Kim, Zurawski, Wang (bib14) 2018; 78 Ridker, MacFadyen, Thuren, Everett, Libby, Glynn (bib11) 2017; 390 Das (10.1016/j.ccell.2021.04.011_bib4) 2020; 80 Segovia (10.1016/j.ccell.2021.04.011_bib12) 2019; 35 Hickish (10.1016/j.ccell.2021.04.011_bib6) 2017; 18 Mantovani (10.1016/j.ccell.2021.04.011_bib9) 2019; 50 Khazim (10.1016/j.ccell.2021.04.011_bib8) 2018; 281 Ridker (10.1016/j.ccell.2021.04.011_bib11) 2017; 390 Apte (10.1016/j.ccell.2021.04.011_bib1) 2006; 25 Wu (10.1016/j.ccell.2021.04.011_bib14) 2018; 78 Fridman (10.1016/j.ccell.2021.04.011_bib5) 2017; 14 Wong (10.1016/j.ccell.2021.04.011_bib13) 2020; 80 Kaplanov (10.1016/j.ccell.2021.04.011_bib7) 2019; 116 Norelli (10.1016/j.ccell.2021.04.011_bib10) 2018; 24 Balkwill (10.1016/j.ccell.2021.04.011_bib2) 2001; 357 Coussens (10.1016/j.ccell.2021.04.011_bib3) 2013; 339 |
| References_xml | – volume: 80 start-page: 5597 year: 2020 end-page: 5605 ident: bib13 article-title: Inhibition of IL1β by Canakinumab May Be Effective against Diverse Molecular Subtypes of Lung Cancer: An Exploratory Analysis of the CANTOS Trial publication-title: Cancer Res. – volume: 18 start-page: 192 year: 2017 end-page: 201 ident: bib6 article-title: MABp1 as a novel antibody treatment for advanced colorectal cancer: a randomised, double-blind, placebo-controlled, phase 3 study publication-title: Lancet Oncol. – volume: 78 start-page: 5243 year: 2018 end-page: 5258 ident: bib14 article-title: IL1 Receptor Antagonist Controls Transcriptional Signature of Inflammation in Patients with Metastatic Breast Cancer publication-title: Cancer Res. – volume: 14 start-page: 717 year: 2017 end-page: 734 ident: bib5 article-title: The immune contexture in cancer prognosis and treatment publication-title: Nat. Rev. Clin. Oncol. – volume: 357 start-page: 539 year: 2001 end-page: 545 ident: bib2 article-title: Inflammation and cancer: back to Virchow? publication-title: Lancet – volume: 24 start-page: 739 year: 2018 end-page: 748 ident: bib10 article-title: Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells publication-title: Nat. Med. – volume: 390 start-page: 1833 year: 2017 end-page: 1842 ident: bib11 article-title: Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial publication-title: Lancet – volume: 339 start-page: 286 year: 2013 end-page: 291 ident: bib3 article-title: Neutralizing tumor-promoting chronic inflammation: a magic bullet? publication-title: Science – volume: 35 start-page: 767 year: 2019 end-page: 781.e6 ident: bib12 article-title: Targeting TMEM176B Enhances Antitumor Immunity and Augments the Efficacy of Immune Checkpoint Blockers by Unleashing Inflammasome Activation publication-title: Cancer Cell – volume: 25 start-page: 387 year: 2006 end-page: 408 ident: bib1 article-title: The involvement of IL-1 in tumorigenesis, tumor invasiveness, metastasis and tumor-host interactions publication-title: Cancer Metastasis Rev. – volume: 80 start-page: 1088 year: 2020 end-page: 1101 ident: bib4 article-title: Tumor Cell-Derived IL1β Promotes Desmoplasia and Immune Suppression in Pancreatic Cancer publication-title: Cancer Res. – volume: 281 start-page: 40 year: 2018 end-page: 56 ident: bib8 article-title: Interleukin 1 gene polymorphism and susceptibility to disease publication-title: Immunol. Rev. – volume: 116 start-page: 1361 year: 2019 end-page: 1369 ident: bib7 article-title: Blocking IL-1β reverses the immunosuppression in mouse breast cancer and synergizes with anti-PD-1 for tumor abrogation publication-title: Proc. Natl. Acad. Sci. USA – volume: 50 start-page: 778 year: 2019 end-page: 795 ident: bib9 article-title: Interleukin-1 and Related Cytokines in the Regulation of Inflammation and Immunity publication-title: Immunity – volume: 24 start-page: 739 year: 2018 ident: 10.1016/j.ccell.2021.04.011_bib10 article-title: Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells publication-title: Nat. Med. doi: 10.1038/s41591-018-0036-4 – volume: 281 start-page: 40 year: 2018 ident: 10.1016/j.ccell.2021.04.011_bib8 article-title: Interleukin 1 gene polymorphism and susceptibility to disease publication-title: Immunol. Rev. doi: 10.1111/imr.12620 – volume: 390 start-page: 1833 year: 2017 ident: 10.1016/j.ccell.2021.04.011_bib11 article-title: Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial publication-title: Lancet doi: 10.1016/S0140-6736(17)32247-X – volume: 78 start-page: 5243 year: 2018 ident: 10.1016/j.ccell.2021.04.011_bib14 article-title: IL1 Receptor Antagonist Controls Transcriptional Signature of Inflammation in Patients with Metastatic Breast Cancer publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-18-0413 – volume: 18 start-page: 192 year: 2017 ident: 10.1016/j.ccell.2021.04.011_bib6 article-title: MABp1 as a novel antibody treatment for advanced colorectal cancer: a randomised, double-blind, placebo-controlled, phase 3 study publication-title: Lancet Oncol. doi: 10.1016/S1470-2045(17)30006-2 – volume: 35 start-page: 767 year: 2019 ident: 10.1016/j.ccell.2021.04.011_bib12 article-title: Targeting TMEM176B Enhances Antitumor Immunity and Augments the Efficacy of Immune Checkpoint Blockers by Unleashing Inflammasome Activation publication-title: Cancer Cell doi: 10.1016/j.ccell.2019.04.003 – volume: 116 start-page: 1361 year: 2019 ident: 10.1016/j.ccell.2021.04.011_bib7 article-title: Blocking IL-1β reverses the immunosuppression in mouse breast cancer and synergizes with anti-PD-1 for tumor abrogation publication-title: Proc. Natl. Acad. Sci. USA doi: 10.1073/pnas.1812266115 – volume: 80 start-page: 5597 year: 2020 ident: 10.1016/j.ccell.2021.04.011_bib13 article-title: Inhibition of IL1β by Canakinumab May Be Effective against Diverse Molecular Subtypes of Lung Cancer: An Exploratory Analysis of the CANTOS Trial publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-19-3176 – volume: 50 start-page: 778 year: 2019 ident: 10.1016/j.ccell.2021.04.011_bib9 article-title: Interleukin-1 and Related Cytokines in the Regulation of Inflammation and Immunity publication-title: Immunity doi: 10.1016/j.immuni.2019.03.012 – volume: 339 start-page: 286 year: 2013 ident: 10.1016/j.ccell.2021.04.011_bib3 article-title: Neutralizing tumor-promoting chronic inflammation: a magic bullet? publication-title: Science doi: 10.1126/science.1232227 – volume: 14 start-page: 717 year: 2017 ident: 10.1016/j.ccell.2021.04.011_bib5 article-title: The immune contexture in cancer prognosis and treatment publication-title: Nat. Rev. Clin. Oncol. doi: 10.1038/nrclinonc.2017.101 – volume: 357 start-page: 539 year: 2001 ident: 10.1016/j.ccell.2021.04.011_bib2 article-title: Inflammation and cancer: back to Virchow? publication-title: Lancet doi: 10.1016/S0140-6736(00)04046-0 – volume: 25 start-page: 387 year: 2006 ident: 10.1016/j.ccell.2021.04.011_bib1 article-title: The involvement of IL-1 in tumorigenesis, tumor invasiveness, metastasis and tumor-host interactions publication-title: Cancer Metastasis Rev. doi: 10.1007/s10555-006-9004-4 – volume: 80 start-page: 1088 year: 2020 ident: 10.1016/j.ccell.2021.04.011_bib4 article-title: Tumor Cell-Derived IL1β Promotes Desmoplasia and Immune Suppression in Pancreatic Cancer publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-19-2080 |
| SSID | ssj0016179 |
| Score | 2.612471 |
| SecondaryResourceType | review_article |
| Snippet | Interleukin-1 (IL-1) is a key orchestrator of inflammation and plays an important role in tumor progression. Based on preclinical models and human genetic... |
| SourceID | proquest pubmed crossref elsevier |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 1023 |
| SubjectTerms | Antibodies, Monoclonal, Humanized - therapeutic use Humans Interleukin 1 Receptor Antagonist Protein - pharmacology Interleukin-1 - genetics Interleukin-1 - metabolism Lung Neoplasms - metabolism Lung Neoplasms - pathology Molecular Targeted Therapy - methods Neoplasms - drug therapy Neoplasms - metabolism Neoplasms - pathology Tumor Microenvironment |
| Title | Interleukin-1 in tumor progression, therapy, and prevention |
| URI | https://dx.doi.org/10.1016/j.ccell.2021.04.011 https://www.ncbi.nlm.nih.gov/pubmed/33989512 https://www.proquest.com/docview/2528181476 |
| Volume | 39 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV27TsMwFLWqDogF8aY8qiAxNmr8jsUEFVUBlQUqdbMS25HCI61KMvD32E5SiaEdGBPbinVs33ts33sCwI3CGBKK4lDHTIREEbvmtEKhTiOMMWMRMS4befrCJjPyNKfzDhi1uTAurLKx_bVN99a6eTNs0Bwu83z4ateqc_4xciqi0Gewu6xSl8Q3v1_fJFgPLWrNVBq62q3ykI_xUu503G4SEfR6pxBu8k6b2Kf3QuN9sNfQx-Cu7uEB6JjiEOxMmwvyI3DrT_g-TfWRFyEM8iIoq6_FKvBhWLUExyCoc65-BkFSaFtimpDHYzAbP7yNJmHzf4RQkYiUIaaYU6q40IJECWeaWmS5sASDY650yrWhJIVpzJWKsdYqJiZhglGSJRnWEJ-AbrEozBkIMpFRZdmQxnbDiKgRBlHNtNA45RilUQ-gFhepGvFw9w-LT9lGib1LD6Z0YMqISAtmDwzWjZa1dsb26qwFXP6ZAtJa9-0Nr9vhkXZxuOKkMIvqWyLqxK4g4awHTutxW_cEYxFbeonO__vZC7Drnnw0oLgE3XJVmSvLUMq0b7n543PfT8RfXLHhlg |
| linkProvider | Elsevier |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1NT8IwGG4IJurF-C1-zsQjC-v3Gk9KJKDARUi4NVtbEhQHQTj47227jcQDHLyubdY8bd_3afu-TwF4UBhDQlEc6piJkChi15xWKNRphDFmLCLGZSP3-qw9JK8jOqqAZpkL48IqC9uf23RvrYsvjQLNxnwyabzbteqcf4yciih0Gew7lg1Ebmp3Rs_rqwTrokUumkpDV72UHvJBXsodj9tdIoJe8BTCTe5pE_30bqh1CA4K_hg85V08AhWTHYPdXnFDfgIe_RHf1Kw-J1kIg0kWLFdfs0Xg47ByDY56kCdd_dSDJNO2xBQxj6dg2HoZNNth8UBCqEhEliGmmFOquNCCRAlnmlpoubAMg2OudMq1oSSFacyVirHWKiYmYYJRMk7GWEN8BqrZLDMXIBiLMVWWDmlsd4yIGmEQ1UwLjVOOURrVACpxkapQD3ePWExlGSb2IT2Y0oEpIyItmDVQXzea5-IZ26uzEnD5Zw5Ia963N7wvh0fa1eGKk8zMVt8SUad2BQlnNXCej9u6JxiL2PJLdPnf396Bvfag15XdTv_tCuy7Eh8aKK5BdblYmRtLV5bprZ-Ov3WO48A |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Interleukin-1+in+tumor+progression%2C+therapy%2C+and+prevention&rft.jtitle=Cancer+cell&rft.au=Garlanda%2C+Cecilia&rft.au=Mantovani%2C+Alberto&rft.date=2021-08-09&rft.issn=1878-3686&rft.eissn=1878-3686&rft.volume=39&rft.issue=8&rft.spage=1023&rft_id=info:doi/10.1016%2Fj.ccell.2021.04.011&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1535-6108&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1535-6108&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1535-6108&client=summon |